MBX Biosciences (NASDAQ:MBX) Stock Rating Upgraded by Wall Street Zen

Key Points

• MBX Biosciences has been upgraded from a "sell" rating to a "hold" rating by Wall Street Zen, signaling improved investor sentiment.
• The company's stock opened at $10.83 with a twelve-month trading range from $4.81 to $27.50, reflecting significant volatility.
• MBX Biosciences specializes in developing precision peptide therapies aimed at treating endocrine and metabolic disorders, leveraging their proprietary PEPTM platform.

Wall Street Zen upgraded shares of MBX Biosciences (NASDAQ:MBX - Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

MBX Biosciences Price Performance

NASDAQ MBX traded up $0.13 on Friday, hitting $10.07. 376,262 shares of the company's stock were exchanged, compared to its average volume of 338,436. MBX Biosciences has a 52 week low of $4.81 and a 52 week high of $27.50. The stock has a market capitalization of $338.25 million and a PE ratio of -2.22.

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.